The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. https://haseebnzzs440807.wikicorrespondence.com/6038657/glp_3_retatrutide_a_comparative_analysis